There are 2789 resources available
154P - Five-year follow-up of the phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in patients with HER2 positive early or locally advanced breast cancer
Presenter: Xavier Pivot
Session: ePoster Display
145P - High-risk breast cancer patients with RAD51-low tumors are characterized by good prognosis
Presenter: Benedetta Pellegrino
Session: ePoster Display
92P - First-results of the CLIMB360 study, a prospective molecular screening program across multiple cancer types based on circulating tumor DNA (ctDNA)
Presenter: Javier Garcia-Corbacho
Session: ePoster Display
263P - Predicting bevacizumab efficacy in mTNBC
Presenter: Heba Bakri
Session: ePoster Display
96P - Real-world single institution clinical outcome study of the impact of comprehensive genomic profiling (CGP) on targeted therapy selection and cancer patient survival
Presenter: Bhaskara Reddy Madhira
Session: ePoster Display
99P - The differentially fragmented regions in cell-free DNA of colorectal cancer patients
Presenter: Dmitry Shcherbo
Session: ePoster Display
101P - The landscape of MET alterations in European cancer patients
Presenter: Jürgen Wolf
Session: ePoster Display
102P - NTRK test usage practices in Europe and Asia: Findings from a real-world study
Presenter: Kriti Jindal
Session: ePoster Display
269P - Patient-reported outcomes (PRO) with talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm): Subgroup analysis of pts with and without TALA dose reductions vs PCT in the EMBRACA trial
Presenter: Hope Rugo
Session: ePoster Display